Evaluation of IGFBP5 expression and plasma osteopontin level in COVID-19 patients

Basit Öğe Kaydı
dc.authoridKerget, Ferhan/0000-0002-5160-4854
dc.contributor.authorUzuncakmak, Sevgi Karabulut
dc.contributor.authorAksakal, Alperen
dc.contributor.authorKerget, Ferhan
dc.contributor.authorAydin, Pelin
dc.contributor.authorHalici, Zekai
dc.date.accessioned2024-10-04T18:49:46Z
dc.date.available2024-10-04T18:49:46Z
dc.date.issued2023
dc.departmentBayburt Üniversitesien_US
dc.description.abstractPurpose: The aim of this study is to investigate insulin-like growth factor binding protein 5 (IGFBP5) expression in coronavirus disease 2019 (COVID-19) patients and its relationships with COVID-19 laboratory findings and plasma osteopontin (OPN) levels.Materials and methods: We enrolled 60 patients with COVID-19 and 30 healthy individuals in this study. mRNA expression of IGFBP5 was measured by RT-PCR. Plasma OPN levels were measured via the ELISA method.Results: Plasma OPN levels were higher and IGFBP5 expression levels were lower in COVID-19 patients than in the healthy individuals (p = 0.0057 and p = 0.0142, respectively). Critically ill patients had higher OPN and lower IGFBP5 than non-critically ill patients. Patients with affected lungs demonstrated increased OPN and decreased IGFBP5 (p = 0.00032 and p = 0.044, respectively). Receiver operating characteristic (ROC) analysis indicated that IGFBP5 expression and OPN levels can be used discriminate non-critically from critically ill patients (p = 0.049; p = 0.0016, respectively).Conclusion: This study demonstrated that patients with a poor prognosis had increased OPN and decreased IGFBP5. High values of OPN and low values of IGFBP5 may be considered as signs of disease severity. Tissue -specific IGFBP5 expression may contribute to understanding the role of IGFBP5 in the lungs in COVID-19 cases.en_US
dc.description.sponsorshipBayburt University Scientific Research Projects Coordination Department; [2021/69001-01-03]en_US
dc.description.sponsorshipFinancial disclosure This research was supported by Bayburt University Scientific Research Projects Coordination Department (Project Number: 2021/69001-01-03) . The funders had no role in the study design, data collec-tion and analysis, decision to publish, or manuscript preparation.en_US
dc.identifier.doi10.1016/j.advms.2022.11.001
dc.identifier.endpage37en_US
dc.identifier.issn1896-1126
dc.identifier.issn1898-4002
dc.identifier.issue1en_US
dc.identifier.pmid36427358en_US
dc.identifier.scopus2-s2.0-85142455260en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage31en_US
dc.identifier.urihttps://doi.org/10.1016/j.advms.2022.11.001
dc.identifier.urihttp://hdl.handle.net/20.500.12403/3279
dc.identifier.volume68en_US
dc.identifier.wosWOS:000895019900004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Urban & Partner Sp Z O Oen_US
dc.relation.ispartofAdvances in Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjectIGFBP5en_US
dc.subjectOsteopontinen_US
dc.subjectCritically ill patientsen_US
dc.subjectOPNen_US
dc.titleEvaluation of IGFBP5 expression and plasma osteopontin level in COVID-19 patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu